U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C6H5O7.3Zn
Molecular Weight 574.426
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC CITRATE

SMILES

[Zn++].[Zn++].[Zn++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=WGIWBXUNRXCYRA-UHFFFAOYSA-H
InChI=1S/2C6H8O7.3Zn/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6

HIDE SMILES / InChI
Molecular Formula C6H5O7
Molecular Weight 189.0997
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity

There is no available information related any biological or pharmacutical application of AMMONIUM PENTACHLOROZINCATE

CNS Activity

Originator

Protherics
40
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

1921
1447
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8228
Activator
1410
Activator
1410
Hydrolytic Enzyme
38
Target ID: ultraviolet B-induced damage
Interacts
321
Activator
1410
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1059
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1059
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8360
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

-4.55328006E11
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8360
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

1.32675836E12
Primary
Approved
8360
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

1.140048E12
Primary
Approved
8360
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8360
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
Phase III
663
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
Phase III
663
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
PubMed

PubMed

TitleDatePubMed
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.
1991 Sep 10
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.
1993 Aug
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
1997 Feb
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.
2000 Sep
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.
2004
Impact of the mother's zinc deficiency on the woman's and newborn's health status.
2005
Erythrocyte zinc content in critically ill patients.
2005
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2.
2005 Apr 27
Zinc in attention-deficit/hyperactivity disorder.
2005 Aug
Low dietary zinc decreases erythrocyte carbonic anhydrase activities and impairs cardiorespiratory function in men during exercise.
2005 May
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet.
2005 Nov-Dec
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.
2005 Sep 1
Effects of zinc supplementation in patients with type 1 diabetes.
2005 Summer
Effect of end-stage renal disease and diabetes on zinc and copper status.
2006 Jul
Elevated cortical zinc in Alzheimer disease.
2006 Jul 11
The effect of Ramadan on maternal nutrition and composition of breast milk.
2006 Jun
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.
2006 May
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.
2006 May
Zinc homeostasis in aging: two elusive faces of the same "metal".
2006 Summer
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.
2007 May
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells.
2009 Mar 28
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.
2010 Dec
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.
2010 Dec 1
Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles.
2010 Dec 15
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.
2010 Jan 12
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010 Oct
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.
2011 Mar 21
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.
2011 Sep
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012 Feb
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.
2012 Jun 25
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012 Mar
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide.
2012 Mar
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014 May 16
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design.
2015
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.
2016 Mar 5
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process.
2016 Oct
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
Rats: The dose of zinc hydroxide administered to each rat was 85 mg/kg and represented 40% of the recommended daily allowance of a male adult human. This dose was administered in water solution at a final volume of 1 mL per rat.
Route of Administration: Oral
In Vitro Use Guide
Zinc hydroxide (1 mM) stimulates superoxide production by rat alveolar macrophages, as determined by CLA-dependent chemiluminescence.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:34:53 UTC 2023
Edited
by admin
on Wed Jul 05 22:34:53 UTC 2023
Record UNII
K72I3DEX9B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC CITRATE
INCI   MART.   MI   WHO-DD  
INCI  
Official Name English
CITRATED ZINC [VANDF]
Common Name English
2-HYDROXY-1,2,3-PROPANETRICARBOXYLIC ACID ZINC SALT
Common Name English
ZINC CITRATE [INCI]
Common Name English
ZINC CITRATE [MART.]
Common Name English
ZINC CITRATE [MI]
Common Name English
Zinc citrate [WHO-DD]
Common Name English
CITRATED ZINC
VANDF  
Common Name English
Classification Tree Code System Code
DSLD 137 (Number of products:9660)
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID90889427
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
PRIMARY
ECHA (EC/EINECS)
208-901-2
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
PRIMARY
DRUG BANK
DB11154
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
PRIMARY
EVMPD
SUB15754MIG
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
PRIMARY
NCI_THESAURUS
C84247
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
PRIMARY
DAILYMED
K72I3DEX9B
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
CONCEPT Dietary Supplement
RXCUI
236911
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
PRIMARY RxNorm
MERCK INDEX
M11603
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
PRIMARY Merck Index
SMS_ID
100000089512
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
PRIMARY
PUBCHEM
11023
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
PRIMARY
FDA UNII
K72I3DEX9B
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
PRIMARY
CAS
546-46-3
Created by admin on Wed Jul 05 22:34:53 UTC 2023 , Edited by admin on Wed Jul 05 22:34:53 UTC 2023
PRIMARY
Related Record Type Details
Structure of ZINC CITRATE DIHYDRATE
SOLVATE->ANHYDROUS
Structure of ZINC CATION
PARENT -> SALT/SOLVATE
Structure of ZINC CITRATE TRIHYDRATE
SOLVATE->ANHYDROUS
Structure of ANHYDROUS CITRIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ZINC CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966